Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Comparison of SARS-CoV-2 serological tests with different antigen targets

Alix T. Coste\textsuperscript{a,\ast}, Katia Jaton\textsuperscript{a}, Matthaios Papadimitriou-Olivergeris\textsuperscript{b,c}, Gilbert Greub\textsuperscript{a}, Antony Croxatto\textsuperscript{a}

\textsuperscript{a} Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
\textsuperscript{b} Service of Hospital Preventive Medicine, Lausanne University Hospital, Switzerland
\textsuperscript{c} Service of Infectious Diseases, Lausanne University Hospital, Switzerland

\section*{ARTICLE INFO}

\begin{abstract}
\textbf{Background:} These last months, dozens of SARS-CoV-2 serological tests have become available with varying performances. A major effort was completed to compare 17 serological tests available in April 2020 in Switzerland.

\textbf{Methods:} In a preliminary phase, we compared 17 IgG, IgM, IgA and pan Ig serological tests including ELISA, LFA, CLIA and ECLIA on a panel of 182 sera, comprising 113 sera from hospitalized patients with a positive RT-PCR, and 69 sampled before 1st November 2019, expected to give a positive and negative results, respectively. In a second phase, the five best performing and most available tests were further evaluated on a total of 582 sera (178 and 404 expected positive and negative, respectively), allowing the assessment of 20 possible cross-reactions with other viruses.

\textbf{Results:} In the preliminary phase, among eight IgG/pan-Ig ELISA or CLIA/ECLIA tests, five had a sensitivity and specificity above 90 \% and 98 \% respectively, and on six IgM/IgA tests, only one was acceptable. Only one LFA test on three showed good performances for both IgG and IgM. For all the tests IgM and IgG aroused concomitantly. In the second phase, no test showed particular cross-reaction. We observed an important heterogeneity in the development of the antibody response.

\textbf{Conclusions:} The majority of the evaluated tests exhibited high performances of IgG/pan-Ig sensitivity and specificity to detect the serological response of moderately to critically ill hospitalized patients. The IgM and IgA tests showed mostly insufficient performances with no added value for the early diagnostic on the cohort tested in this study.
\end{abstract}

1. Introduction

In December 2019, a new virus causing severe respiratory infections emerged in China in the Wuhan area. This virus was classified in the Coronaviridae family and in the \textit{Beta}coronavirus genus, named SARS-CoV-2 (Severe \textit{A}cute \textit{R}espiratory \textit{S}yndrome \textit{C}orona\textit{V}irus 2) and the associated disease was coined “COVID-19” (COrona\textit{V}irus Disease 2019). The epidemic rapidly spread and the WHO classified it as a pandemic in March 2020 (https://www.who.int/news-room/detail/27-04-2020-who-timeline—covid-19).

The mortality rate of the SARS-CoV-2 (about 2\%) is lower than SARS-CoV-1 and MERS-CoV (Middle East Respiratory Syndrome Coronavirus) (10 and 30 \%, respectively) but its reproduction rate $R_0$ (2–2.5) is higher, than the SARS-CoV-1 (1.7–1.9) and the MERS-CoV (<1), probably explaining its rapid spreading worldwide [1–3].

In a first phase of the pandemic, nucleic acid amplification tests (NAAT) enabled rapid detection of infected patients, their sorting and their possible isolation. In a second phase, serology testing appeared particularly important as it permits to diagnose patients after the acute phase of the infection or with atypical clinical presentation with no nasopharyngeal shedding of the virus [4,5]. Indeed, in contrast to NAAT, which must be carried out when and where the virus is excreted, the serological assays might be performed anytime ideally more than two weeks after symptoms onset [4]. Serology also appeared to be the test of choice to perform large-scale population prevalence studies.

Various SARS-CoV-2 serological tests using different targeted antigenic proteins have been arriving on the market the last months (https://www.finddx.org/covid-19/pipeline). Some of them use whole virus lysate, recombinant full S (spike) or N (nucleocapsid) proteins, peptides of the N or specific domains S1, S2 or RBD (receptor-binding proteins).
domains) of the S protein.

Different studies demonstrated that the S and N proteins were the most immunogenic [4,6–8]. The N protein is relatively small with no glycosylated sites and presents a higher level of conservation than the S protein among coronavirus infecting human, allowing possible false positive results through cross-reaction [4,9,10]. In contrast the S protein is a large transmembrane protein, less conserved, containing several glycosylated sites and bearing a more complex conformation, leading to production of more specific antibodies often recognizing conformational or glycosylated epitopes [9–11]. Thus the use of recombinant S protein lacking glycosylation or conformation in immunoassays may lead to false negative results.

In this study we evaluated several SARS-CoV-2 serological tests available in April 2020 in Switzerland including ELISA (Enzyme-Linked ImmunoSorbent Assays), LFA (Lateral Flow ImmunoAssays), CLIA (Chemiluminescent ImmunoAssays) or ECLIA (Electro-Chemiluminescent ImmunoAssays). This evaluation aimed to identify high quality tests for symptomatic patients.

2. Material and methods

2.1. Samples

The first phase of the evaluation was performed on 182 sera (113 positive and 69 negative) (Table S1). Then, the evaluation was completed for the selected tests on 400 sera (65 positive and 335 negative), leading to a full evaluation performed on 582 sera (178 positive and 404 negative) (Table S1). Negative-expected sera were selected among sera sampled before the 1st November 2019 and indicated as “Anterior” for anterior to SARS-CoV-2 pandemic (Table S1). Possible cross-reactivity was assessed through testing of sera known to be positive for a given microorganism, indicated as “Anterior (micro-organism)”. The 178 expected positive sera were sampled during the first 2 months post-symptoms from patients documented with a positive SARS-CoV-2 RT-PCR and with a dates of symptoms in their electronic records.

2.2. ELISA, LFA, and CLIA assays

Each test (Table S2) was performed according to the manufacturers’ instructions. ELISA assays were done in duplicates and manually to diminish dead volume, except washing steps performed with a microplate washer (PW40, Bio-Rad, France). Reading of the optical densities (OD) was done with a microplate reader (800 TSI, BioTek, USA).

For CLIA assays, the LIASON® SARS-CoV-2 IgG kit was performed on a Liaison® XL (DiaSorin, Italy), and the MAGLUMITM 2019-nCoV IgG and IgM kits on a MAGLUMITM 800 (Snibe, China). The ECLIA assay, Elecsys anti-SARS-CoV-2 was performed on a COBAS 6000 (Roche, Switzerland).

Sensitivity was evaluated on expected positive sera according to day post-symptoms. Specificity was determined on expected negative sera sampled before 1st November 2019.

2.3. Statistical analyses

Sensitivity and specificity with 95 % CI (Wilson/Brown method of GraphPad Prism 8.3.0) were calculated with Excel and GraphPad prims.

3. Results

3.1. Preliminary evaluation of 17 SARS-CoV-2 serologic tests

A preliminary evaluation of 17 serological kits (Table S2) has been performed on 182 sera, including 113 sera from patients positive for a SARS-CoV-2 RT-PCR (considered as positive) and 69 sera sampled before November 1, 2019 (considered as negative). For the 113 so-called “positive sera”, a stratification of the results was done according to the time between symptoms onset and sera sampling. Four categories were defined 0–5, 6–10, 11–15 and >15 days. The 17 serological kits tested included 10 ELISA (five IgG, three IgM, one IgA, and one IgM + IgA) from five manufacturers, three LFA (IgG + IgM) from three manufacturers, three CLIA (two IgG and one IgM) from two manufacturers, and one ECLIA (pan-Ig).

For all the 17 tests (IgG, IgM, IgA, pan-Ig) the sensitivity increased over time post-symptoms as expected (Fig. 1, Table S3–5). Concerning IgG or pan-Ig tests, a sensitivity above 70 % was obtained after 10 days post-symptoms for almost all tests except the Diasorin ISO® SARS-CoV-2 IgG kit (57 %). However, a sampling at minimum 15 days post-symptoms is necessary for most of the IgG/pan-Ig tests to reach more than 90 % sensitivity (Figs. 1 and 2, Table S3–5). Only three tests exhibited a sensitivity lower than 90 % more than 15 days post-symptoms, the Euroimmun IgG LFA test (88 %, CI:72–95), the NADAL® COVID-19 IgG/IgM LFA test (84 %; 95 % CI:67–93) and the Diasorin ISO® SARS-CoV-2 IgG CLIA kit (83 %, 95% CI:66–93) (Fig. 2, Table S3–5). All the IgG tests except the SARS-CoV-2 NP IgG ELISA Kit from ImmunoDiagnostic limited presented a specificity equal or above 97 %. Noteworthy, none of the IgG test has shown specific cross-reactivity with sera from patients documented with a positive RT-PCR for Human seasonal coronavirus E229, OC43, HKU1, and NL63.

The only IgM/IgA tests, exhibiting satisfying performances (sensitivity of at least 80 % and specificity around 95 %) and higher at least 15 days post-symptoms were the NADAL LFA (sensitivity: 94 %, 95 % CI:80–99; specificity: 99 %, 95 % CI:92–100), the Dynamiker LFA (sensitivity: 94 %, 95 % CI:79–99; specificity: 93 %, 95 % CI:84–97), and the CLIA from Snibe (sensitivity: 80 %, 95 % CI:63–90; specificity: 99 %, 95 % CI: 92–100) (Fig. 2, Table S3–5).

The other tests, Epitope Diagnostic (ED) IgM ELISA, Euroimmun IgA ELISA, Vircell IgM + IgA ELISA, ImmunoDiagnostic limited IgM ELISA demonstrated insufficient performances (Fig. 2, Table S3–5).

Concerning the LFA, IgG and IgM being tested simultaneously, both tests should give excellent results to be valuable. The Dynamiker IgG/IgM LFA is the only test respecting a sensitivity and specificity of more than 90 % for both lg after 15 days post-symptoms. Interestingly, we observed a simultaneous IgM and IgG response overtime for the tests with an IgM specificity above 90 % (Dynamiker LFA, NADAL LFA and Snibe CLIA) (Fig. 1).

3.2. Complete evaluation of 5 SARS-CoV-2 selected serologic tests

Following the preliminary evaluation, the ED IgG ELISA, the Dynamiker IgG/IgM LFA, the Diasorin IgG CLIA and the Snibe IgG and IgM CLIA tests were thus selected for further analyses based on i) sensitivity and specificity performance of the preliminary evaluation, ii) diversity of targeted antigens (anti-N: ED IgG ELISA and Dynamiker IgG/IgM; anti-S: Diasorin IgG CLIA, anti-N + S: Snibe IgG/IgM CLIA) iii) availability of the kits at the later on 15th April 2020 in Switzerland, iv) specific detection of IgG and/or IgM or IgA and v) compatibility of the kits to most laboratory needs including median to low samples volumes per day and extended expiration days upon kits opening. For instance, despite its good performance, the ECLIA from Roche was not selected as it detects pan-Ig, which is not the most appropriate for infectious serology diagnostic. In addition, the 200 tests expired 2 days upon kits opening which requires large sample volumes.

All the five selected tests were further evaluated on 65 positive and 335 negative sera to end-up with a global evaluation performed on 178 positive and 404 negative for a total of 586 sera (Fig. 3, Table S1). The negative sera were chosen to assess possible cross-reactivity with human viral infections other than human coronavirus: Herpes simplex virus 1 and 2, Respiratory Syncytial Virus, Epstein-Barr virus, Cytomegalovirus, Mumps virus, Measles virus, Parvovirus B19, Rubella virus, Tick-borne encephalitis virus, Influenza A and B, Varicella-zoster virus, Human Immunodeficiency virus, Hepatitis A, B, C, D, and E, and some
rheumatoid factors, or auto-antibodies (anti-PR3, -PR4, SCL70, SCL71).

The four IgG tests demonstrated good sensitivity (≥96 %) and specificity (≥98 %) performances at more than 15 days post-symptoms, except the Diasorin ISON® SARS-CoV-2 IgG CLIA kit that showed a sensitivity of 92 % (95 % CI: 83–96) but with a specificity of 100 % (Fig. 4, Table S6). The IgM tests exhibited a sensitivity of 91 % (95 % CI: 95–92), and a specificity of 98 % (95 % CI: 96–99) for the CLIA Snibe IgM test with a sensitivity of 97 % (95 % CI: 91–100) and a specificity of 96 % (95 % CI: 94–98) for the LFA Dynamiker IgM test (Fig. 4, Table S6).

3.3. Semi-quantitative antibody production

We analyzed the development of the IgG semi-quantitative response overtime post-symptoms with the ED ELISA targeting the anti-N response, the Diasorin CLIA targeting the anti-S1-S2 domains of the S protein, and the Snibe CLIA targeting both N and S proteins (Fig. 5). Among the 178 positive sera, several were sampled from the same patient overtime. We could observe that one patient with ED ELISA, three patients with Diasorin CLIA and two patients with Snibe CLIA became positive for anti-SARS-CoV-2 IgG more than 15 days post-symptoms (Fig. 5). Thus, with the Diasorin CLIA, one patient was negative for two consecutive sera collected at days 17 and 21 post-symptoms and became positive only at day 27 post-symptoms and another patient was negative at 16 days post-symptoms and became positive only 23 days post-symptoms. With the Snibe CLIA, one patient was negative at day 13 post-symptoms and became positive only at day 21 post-symptoms. One patient became positive with all test only 32 days post-symptoms.
4. Discussion

To our knowledge, this study is the first one comparing so many different serologic tests for SARS-CoV-2 diagnostic using different technologies, LFA, ELISA, CLIA and ECLIA, on sera from RT-PCR positive patients collected over one to two months post-symptoms, and assessing 20 possible cross reactions with other viral infections.

This large evaluation of 17 SARS-CoV-2 serological tests highlights in the preliminary phase that among eight IgG/pan-Ig ELISA or CLIA/ECLIA tests, five were recommended with a combined sensitivity above 90 % and specificity above 98 % (Epitope Diagnostic, Vircell and Creative Diagnostic IgG ELISA tests, Snibe IgG CLIA and Roche pan-Ig ECLIA tests), and that on six IgM/IgA ELISA or CLIA/ECLIA tests, only one (Snibe IgM CLIA) was acceptable with a combined sensitivity above 80 % and specificity of 99 %.

Concerning LFA, only one test showed good performances for both IgG and IgM, showing that a thorough evaluation is absolutely required before use especially, outside referenced diagnostic laboratories.

For all different tests, we observed that IgM and IgG aroused concomitantly, as already described for SARS-CoV-1 and 2 infection [5, 12, 13]. However, other studies demonstrated a higher sensitivity of IgM than IgG detection during the first 14 days post-symptoms [14]. It is therefore difficult to determine if the difference observed is due to a difference in IgM and IgG kinetic response between the different cohorts.

Fig. 3. Complete evaluation: Sensitivity at 0-5, 6-10, 11-15 and above 15 days post-symptoms. Specificity is indicated below each graph.

Fig. 4. Complete evaluation: Comparison of the sensitivity and specificity. The sensitivity is given for the sample above 15 days post symptoms.
Previous studies on other coronavirus [4], or on SARS-CoV-2 [16] suggested the usefulness of IgM for the serologic diagnostic of SARS-CoV-2. Our conclusion can thus only be applied to this type of patients.

Additional evaluation studies of these SARS-CoV-2 anti-N and anti-S serological tests need to be performed to assess the performance of these tests on sera collected from non-hospitalized pauci-symptomatic patients, from SARS-CoV-2 RT-PCR positive patients but more than two month post exposure, or from symptomatic SARS-CoV-2 negative RT-PCR patients non tested here for ethical reasons.

Finally, complementarity of both kind of tests (anti-N and anti-S) has clearly been envisaged and evaluated to fulfill the best performances as they might be complementary and might permit to reach the best sensitivity and specificity for both clinical and large seroprevalence population studies.

**Author’s contribution**

ATC and AC wrote the first draft. All authors critically reviewed the manuscript.

**Ethical statement**

This study was evaluated by our Ethics Committee (CER-VD) and they judged that it did not deserve a specific approval being only a quality assessment of diagnostic tests.

**Funding information**

No external funding was necessary to write this study.

**Declaration of Competing Interest**

The authors report no declarations of interest.

**Acknowledgements**

We warmly thank all the members of the laboratory of serology of the CHUV, Sarah Chappuis, Fabienne Di Paola, Carine Pintet Pont, Claudine Gosetely, Emilie Ruegger, Sylvie Caillon-Bouchez, Marijana Vujica, Alexandre Mamin, and Benjamin Gayton, for their wonderful implication in this project, and the set-up of SARS-CoV-2 serologic testing in our hospital. We would like to thank the laboratory of immunology to provide us some sera especially those positive for Lupus, HIV, hepatitis, rheumatoid factors, and auto-antibody. We thank Pr Marchetti Oscar and Pr Pache Antoine from the Ensemble Hospitalier de la Cote, Morges, Switzerland, Dr Caroline Chapuis-Taillard and Dr De Valliere Serge from Clinique de la Source, Lausanne, Switzerland and, Dre Aurelie Jayol-Virely from Clinical laboratory of the Etablissement Hospitalier Nord-Vaudois, Yverdon, Switzerland, to have shared information about the symptoms date of some patients.

---

**Declaration of Competing Interest**

The authors report no declarations of interest.

**Acknowledgements**

We warmly thank all the members of the laboratory of serology of the CHUV, Sarah Chappuis, Fabienne Di Paola, Carine Pintet Pont, Claudine Gosetely, Emilie Ruegger, Sylvie Caillon-Bouchez, Marijana Vujica, Alexandre Mamin, and Benjamin Gayton, for their wonderful implication in this project, and the set-up of SARS-CoV-2 serologic testing in our hospital. We would like to thank the laboratory of immunology to provide us some sera especially those positive for Lupus, HIV, hepatitis, rheumatoid factors, and auto-antibody. We thank Pr Marchetti Oscar and Pr Pache Antoine from the Ensemble Hospitalier de la Cote, Morges, Switzerland, Dr Caroline Chapuis-Taillard and Dr De Valliere Serge from Clinique de la Source, Lausanne, Switzerland and, Dre Aurelie Jayol-Virely from Clinical laboratory of the Etablissement Hospitalier Nord-Vaudois, Yverdon, Switzerland, to have shared information about the symptoms date of some patients.

---

**Declaration of Competing Interest**

The authors report no declarations of interest.

**Acknowledgements**

We warmly thank all the members of the laboratory of serology of the CHUV, Sarah Chappuis, Fabienne Di Paola, Carine Pintet Pont, Claudine Gosetely, Emilie Ruegger, Sylvie Caillon-Bouchez, Marijana Vujica, Alexandre Mamin, and Benjamin Gayton, for their wonderful implication in this project, and the set-up of SARS-CoV-2 serologic testing in our hospital. We would like to thank the laboratory of immunology to provide us some sera especially those positive for Lupus, HIV, hepatitis, rheumatoid factors, and auto-antibody. We thank Pr Marchetti Oscar and Pr Pache Antoine from the Ensemble Hospitalier de la Cote, Morges, Switzerland, Dr Caroline Chapuis-Taillard and Dr De Valliere Serge from Clinique de la Source, Lausanne, Switzerland and, Dre Aurelie Jayol-Virely from Clinical laboratory of the Etablissement Hospitalier Nord-Vaudois, Yverdon, Switzerland, to have shared information about the symptoms date of some patients.

---

**Declaration of Competing Interest**

The authors report no declarations of interest.

**Acknowledgements**

We warmly thank all the members of the laboratory of serology of the CHUV, Sarah Chappuis, Fabienne Di Paola, Carine Pintet Pont, Claudine Gosetely, Emilie Ruegger, Sylvie Caillon-Bouchez, Marijana Vujica, Alexandre Mamin, and Benjamin Gayton, for their wonderful implication in this project, and the set-up of SARS-CoV-2 serologic testing in our hospital. We would like to thank the laboratory of immunology to provide us some sera especially those positive for Lupus, HIV, hepatitis, rheumatoid factors, and auto-antibody. We thank Pr Marchetti Oscar and Pr Pache Antoine from the Ensemble Hospitalier de la Cote, Morges, Switzerland, Dr Caroline Chapuis-Taillard and Dr De Valliere Serge from Clinique de la Source, Lausanne, Switzerland and, Dre Aurelie Jayol-Virely from Clinical laboratory of the Etablissement Hospitalier Nord-Vaudois, Yverdon, Switzerland, to have shared information about the symptoms date of some patients.
Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.jcv.2020.104690.

References

[1] J. Chen, Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses, Microbes Infect. 22 (2) (2020) 69–71.
[2] D. Tang, P. Comish, R. Kang, The hallmarks of COVID-19 disease, PLoS Pathog. 16 (5) (2020) e1008536.
[3] J.T. Wu, K. Leung, G.M. Leung, Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study, Lancet 395 (10225) (2020) 689–697.
[4] B. Meyer, C. Drosten, M.A. Muller, Serological assays for emerging coronaviruses: challenges and pitfalls, Virus Res. 194 (2014) 175–183.
[5] W. Zhang, et al., Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes, Emerg. Microbes Infect. 9 (1) (2020) 386–389.
[6] M. Qiu, et al., Antibody responses to individual proteins of SARS coronavirus and their neutralization activities, Microbes Infect. 7 (5-6) (2005) 882–889.
[7] L. Premkumar, et al., The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients, Sci. Immunol. 5 (48) (2020).
[8] W. Tai, et al., Identification of SARS-CoV RBID-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2, Antiviral Res. 179 (2020) 104820.
[9] M. Infantino, Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives, Int. Med. Assoc. J. 22 (4) (2020) 203–210.
[10] Okhs, N.M.A., et al., 2020.
[11] A.C. Walls, et al., Structure, function, and Antigenicity of the SARS-CoV-2 spike glycoprotein, Cell 181 (2) (2020) 281–292, e6.
[12] P.C. Woo, et al., Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus, Clin. Diagn. Lab. Immunol. 11 (4) (2004) 665–668.
[13] K.K.-W. To, et al., Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study, Lancet Infect. Dis. 20 (5) (2020) 565–574.
[14] J. Zhao, et al., Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin. Infect. Dis. (2020).
[15] G. Caruana, et al., Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results, CMI (2020). In press.
[16] B. Sun, et al., Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients, Emerg. Microbes Infect. 9 (1) (2020) 940–948.
[17] W.N. Chia, et al., Serological differentiation between COVID-19 and SARS infections, Emerg. Microbes Infect. (2020) 1–23.
[18] F. Amanat, et al., A serological assay to detect SARS-CoV-2 seroconversion in humans, Nat. Med. 26 (7) (2020) 1033–1036.
[19] C. Fenwick, et al., Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies, J. Virol. (2020), https://doi.org/10.1128/JVI.01828-20. In press.
[20] A.T. Coste, et al., Indication for SARS-CoV-2 serology: first month follow-up, Clin. Microbiol. Infect. Dis. (2020). In press.